| Literature DB >> 18097462 |
Peter Karran1, Natalie Attard.
Abstract
Thiopurines have diverse clinical applications and their long-term use as anti-rejection drugs in transplant patients has been associated with a significantly increased risk of various types of cancer. Although they are slowly being replaced by a new generation of non-thiopurine immunosuppressants, it is anticipated that their use in the management of inflammatory and autoimmune diseases will continue to increase. Therapy-related cancer will remain a potential consequence of prolonged treatment for these generally non-life-threatening conditions. Understanding how thiopurines contribute to the development of cancer will facilitate clinical decisions about the potential risks to patients of long-term treatment for chronic inflammatory disorders.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18097462 DOI: 10.1038/nrc2292
Source DB: PubMed Journal: Nat Rev Cancer ISSN: 1474-175X Impact factor: 60.716